-
27 domestic innovative drugs will be launched in 2021, reaching new heights
Time of Update: 2022-01-25
Among them, six pharmaceutical companies, including Hengrui Pharmaceutical, Fosun Pharmaceutical, Mindray Medical, Junshi Bio, Shanghai Pharmaceuticals, and Kelun Pharmaceutical, have invested more than 1 billion yuan in research and development .
-
In 2021, a large number of domestic innovative drugs will be terminated
Time of Update: 2022-01-25
On December 28, Fosun Pharma announced that its subsidiary Jiangsu Wanbang had decided to terminate the clinical trial and subsequent development of the SGLT-2 inhibitor vanpagliflozin .
-
Ambroxol hydrochloride oral solution, a subsidiary of Hengrui Medicine, was approved for marketing
Time of Update: 2022-01-25
The approved drug Ambroxol Hydrochloride Oral Liquid can increase the secretion of mucous glands in the respiratory tract and reduce the secretion of mucous glands, thereby reducing the viscosity of sputum, and at the same time promoting the secretion of pulmonary surfactant, increasing the movement of bronchial cilia to make sputum easier to cough up, suitable for For acute and chronic bronchitis caused by thick sputum, difficult expectoration .
-
CDE issued 5 guiding principles involving traditional Chinese medicine, improved new drugs, innovative drugs, etc.
Time of Update: 2022-01-25
The details are as follows: Under the deployment of the State Drug Administration, the Center for Drug Evaluation organized the formulation of the "Technical Guidelines for the Study of Samples for Toxicology Research of New Chinese Medicines (for Trial Implementation)" (see attachment) .
-
The first clinical report of TIGIT monoclonal antibody of Kangfang Bio
Time of Update: 2022-01-25
Source: CDE official websiteAK127 is a TIGIT monoclonal antibody independently developed by the company.
According to the Insight database, there are 7 TIGIT monoclonal antibodies and 4 double-antibodies under development in China.
At present, there are 9 TIGIT monoclonal antibody projects in clinical development in China .
-
Nearly 80% of the new total market capitalization of pharmaceutical companies has increased compared to when they were first listed, with 2 companies increasing by more than 10,000%
Time of Update: 2022-01-25
For example, on the product side, Pien Tze Huang Pharma has invested heavily in innovative research and development, made efforts to master the core technologies of the industrial chain, and strengthened cooperation with many universities and scientific research institutions at home and abroad.
-
In 2022, personnel changes in pharmaceutical companies are becoming more frequent
Time of Update: 2022-01-25
On January 6, Buchang Pharmaceutical announced that Liu Luxiang applied for his resignation as vice president of the company due to personal reasons, and would not hold any position in the company after resignation.
-
JPM Conference: WuXi AppTec's R&D personnel account for over 80% of the total number of Cinda employees over 6,000
Time of Update: 2022-01-24
In addition, domestic companies such as BeiGene and Innovent Bio also disclosed the latest team numbers at the Morgan Conference .
Baiji's R&D team has more than 3,700 people, including 800 overseas, achieving CRO-free; the sales team has more than 3,400 people, including 3,200 domestic and 200 overseas .
-
Key Points of Executive Speeches of 15 Pharmaceutical Giants at JPM Conference
Time of Update: 2022-01-24
Executives said BMS' new product portfolio could generate $25 billion or more in revenue by 2029, while the company is planning to bring seven products to market in mid-to-late development stages .
-
Accelerating the launch of innovative drugs in China, risks and benefits coexist
Time of Update: 2022-01-24
This drug is a new generation of small molecule STING agonists, and no drug with the same target has been approved for marketing .
-
Harmonicare Pharmaceuticals completes the first interim analysis of the Phase III clinical trial of Tenacept
Time of Update: 2022-01-24
On January 12, Harbin Pharmaceutical announced that the Phase III registration clinical trial of its new drug ternacept (HBM9036) in China has completed the first interim analysis .
Tenacept (HBM9036) is a globally innovative tumor necrosis factor (TNF) receptor-1 fragmented drug for adults with moderate to severe dry eye (DED) .
-
At the beginning of the new year, multinational pharmaceutical companies have started the road of "buy, buy, buy"
Time of Update: 2022-01-24
In order to increase the scale of the industry, reduce homogeneous competition, and expand the enterprise, pharmaceutical companies will continue to enrich the product pipeline and improve the research and development strength of innovative drugs .
-
The annual increase of 357 stocks doubled, and pharmaceutical equipment companies performed well
Time of Update: 2022-01-24
According to the author's incomplete statistics, in the pharmaceutical and biological industry, there are at least 19 stocks with an annual increase of more than 100%, including Jiu'an Medical, Gongdong Medical, Boren Medical, Rejing Bio, Tuoxin Pharmaceutical, etc.
-
In 2022, the AI pharmaceutical track is still hot!
Time of Update: 2022-01-24
The two companies will leverage Absci's AI-driven drug innovation platform for drug development; Sanofi announced a research collaboration license agreement of up to $5.
-
Under the AI pharma boom, the layout of pharmaceutical machine companies in this track will continue to accelerate
Time of Update: 2022-01-24
Under the AI pharma boom, pharmaceutical machine companies will accelerate their deployment in this track (Photo source: PharmaNet) Major pharmaceutical companies are accelerating the development of AI drugs Recently, Amgen announced that it has reached a research cooperation agreement with Generate Biomedicines .
-
Gansu improves the level of drug security: new anti-tumor drugs will continue to enter medical insurance
Time of Update: 2022-01-24
At the meeting, Yang Wenbin, director of the Planning, Finance, Policy and Regulation Division of the Gansu Provincial Medical Security Bureau , said in response to reporters' questions that it is necessary to improve the level of treatment for major diseases and the guarantee of medication for special groups, innovate the way of negotiating the guarantee of drug supply, and establish and improve "dual-channel" management.
-
The State Food and Drug Administration issued a revised instruction manual for cimetidine injection preparations
Time of Update: 2022-01-24
5. Provincial drug regulatory authorities shall urge the drug marketing authorization holders of the above-mentioned drugs within the administrative region to do a good job in revising the corresponding instructions and replacing the labels and instructions as required, and strictly investigate and punish violations of laws and regulations in accordance with the law .
-
Flunarizine Hydrochloride Capsules, a wholly-owned subsidiary of Zhendong Pharmaceutical, passed the consistency evaluation of generic drugs
Time of Update: 2022-01-24
On the morning of January 14, Zhendong Pharmaceutical announced that its wholly-owned subsidiary Anxin Bio had received the "Approval Notice for Supplementary Drug Application" issued by the State Drug Administration, and that Flunarizine Hydrochloride Capsules had been approved as a generic drug.
-
The collection of proprietary Chinese medicines is frequent, and the market "shuffle" may speed up
Time of Update: 2022-01-24
However, it is worth noting that, judging from the 19 provinces, autonomous regions and municipalities led by Hubei Province some time ago, the 19 provinces, autonomous regions and municipalities in the alliance opened bids for the centralized procurement of Chinese patent medicines, and the average price dropped by 42.
-
The "14th Five-Year" National Eye Health Plan was issued to focus on the prevention and treatment of eye diseases and the rehabilitation of low vision
Time of Update: 2022-01-24
During the "Thirteenth Five-Year Plan" period, the prevention and control of myopia in children and adolescents was included in the government performance assessment, forming a good atmosphere of "government leadership, department cooperation, expert guidance, school education, and family attention", and ophthalmic medical and health services developed rapidly.
